Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HVTN 137: BG505 SOSIP.664 gp140 Vaccine in Healthy Adults
NCT04177355Phase 1Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Jan 2020
- Primary completion
- Nov 2024
- Modality
- Recombinant Protein Vaccines, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of BG505 SOSIP.664 gp140 in human immunodeficiency virus infection (HIV) (16 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Number of Participants Reporting Local Solicited Adverse Events Signs and Symptoms: Pain and/or Tenderness, Number of Participants Reporting Local Solicited Adverse Events Signs and Symptoms: Erythema and/or Induration and 5 more. Started Jan 2020; status: completed.
02
Drugs
BG505 SOSIP.664 gp140
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT04177355.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04177355.